Japan Tobacco Inc.

Shintaro Hirashima

Hiroshi Yamanaka

Takayuki Sakai

Tetsuya Iida

Masahiro Yokota

Makoto Shiozaki

Satoru Noji

Tomoya Miura

Noriyoshi Seki

Takahiro Oka

Tomoyuki Manabe

Yasushi Niwa

Yoko Matsumoto

Toshihiro Sato

Izuru Ando

Kazutaka Ikegashira

Takaki Maeba

Masayuki Kotoku

Katsuya Maeda

Kazayuki Hirata

Shingo Obika

Kentaro Sakurai

Yukihiro Nomura

Kazuyuki Hirata

Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]: wherein Ris hydrogen or halogen, Ris Calkyl or halo-Calkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof

A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Amide compound and medicinal use thereof

The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor

Growing community of inventors

Osaka, Japan

Shintaro Hirashima